L Brookman

Novartis (United Kingdom) — United Kingdom

Medicine · Health Sciences

12h-index803citations25works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(7), Inhalation and Respiratory Drug Delivery(5), Chronic Obstructive Pulmonary Disease (COPD) Research(4), Advanced Polymer Synthesis and Characterization(4), Allergic Rhinitis and Sensitization(3)

Publications25 total

Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD
International Journal of Clinical Pharmacology and Therapeutics·2011· 12 cited
Bioequivalence of a Novel Omalizumab Solution for Injection Compared with the Standard Lyophilized Powder Formulation
Journal of Bioequivalence & Bioavailability·2011· 24 citedOpen Access
Bronchodilator effects of indacaterol and formoterol in patients with COPD
Pulmonary Pharmacology & Therapeutics·2009· 52 citedOpen Access
Neue flüssige Omalizumab-Formulierung als Fertigspritze ist bioäquivalent zum bisherigen Lyophilisat
Pneumologie·2009
Indacaterol –Überblick über das kardiale Sicherheitsprofil bei COPD
Pneumologie·2009
Kardiale Verträglichkeit von Indacaterol bei Asthma-Patienten
Pneumologie·2009
Vergleich der bronchodilatatorischen Wirksamkeit von Indacaterol und Formoterol bei COPD-Patienten auf FEV1 und Inspiratorische Kapazität
Pneumologie·2009
The Effect of Discontinuing Omalizumab Therapy on Free IgE Concentration
Journal of Allergy and Clinical Immunology·2007· 2 citedOpen Access
Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma
Current Medical Research and Opinion·2007· 30 cited
Single and Multiple Doses of Indacaterol, A Novel Once-Daily β2-Agonist, Are Well Tolerated in Patients with Mild Asthma
Journal of Allergy and Clinical Immunology·2006
Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients
American Journal of Transplantation·2003· 103 citedOpen Access
Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma
Current Medical Research and Opinion·2003· 183 cited
PHARMACOKINETIC (PK) / PHARMACODYNAMIC (PD) MODEL OF FTY 720 IN HUMANS
Transplantation·1999
HUMAN SAFETY AND PHARMACOLOGY OF FTY 720
Transplantation·1999· 11 cited
DOSE SELECTION BY PREDICTION OF HUMAN ORAL CLEARANCE OF FTY 720 USING INTERSPECIES SCALING
Transplantation·1999· 2 cited
A Trial to Investigate the Relationship between DFO Pharmacokinetics and Metabolism and DFO‐Related Toxicity
Annals of the New York Academy of Sciences·1998· 30 cited
Subcutaneous depot desferrioxamine (CGH 749B); Relationship of pharmacokinetics to efficacy and drug metabolism.
UCL Discovery (University College London)·1997· 3 cited
Pharmacokinetics of valsartan in patients with liver disease
Clinical Pharmacology & Therapeutics·1997· 93 cited
Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin
Clinical Pharmacology & Therapeutics·1997· 52 cited
Soluble Polymeric Carriers for Drug Delivery - Part 6: Preparation and Biodistribution of N5-Hydroxyethyl-L-Glutamine-co-L-Glutamic Acid Copolymers in Rats
Journal of Bioactive and Compatible Polymers·1993· 8 cited
page 1 of 2Next →

Frequent Co-authors

Peter Goddard(5), Karel Petrak(5), Robert Schmouder(4), R. Brunkhorst(4), Steven Pascoe(4), S Seyfried(4), Janet Brown(3), John O’Mullane(3), Jutta Beier(3), Abdel Hmissi(3), Neumayer Hh(3), P Lücker(3), Klemens Budde(2), Lusie E.F. Hutchinson(2), Paul Rolan(2), Guy Peachey(2), Brigitte Elharrar(2), John B. Porter(2), Lorraine Stallibrass(2), Christine Reynolds(2)